INT252
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
Combined administration of CLON and PD had an additive effect on GH release (peak: 27.5 +/- 4.5 ng/ml; AUC: 920.8 +/- 153.3 ng/ml/h; p less than 0.005 vs CLON and PD alone). | |||||||||||||||
| |||||||||||||||
|
Acute administration of pyridostigmine and clonidine has an additive stimulatory effect on GH release in normal children. | |||||||||||||||
| |||||||||||||||
|
In conclusion, presented data show that: i) CLON and PD have similar GH-releasing effect in normal children; ii) The additive stimulatory effect on GH release exerted by acute combined administration of CLON and PD agrees with the hypothesized different mechanism of action of these two drugs; iii) A therapeutic association of CLON and PD may be envisaged in the treatment of some children of short stature. | |||||||||||||||
| |||||||||||||||
|
It has been shown in humans that both alpha 2-adrenoceptor activation by clonidine (CLON) and cholinergic enhancement by pyridostigmine (PD) have a clear-cut stimulatory effect on GH release. | |||||||||||||||
| |||||||||||||||
|
Patients achieved similar growth velocities when sustained release GH was given once or twice monthly. | |||||||||||||||
| |||||||||||||||
|
The aim of this work is to study GH release in response to alpha-2 adrenoceptors stimulation by clonidine in obesity. 12 volunteer obese subjects were studied. 10 normal weight subjects, sex and age matched, were controls. | |||||||||||||||
| |||||||||||||||
|
Stimulation of GH release is a well-known effect of clonidine in man. | |||||||||||||||
| |||||||||||||||
|
Obesity is characterized by an impairment of GH release in response to various stimuli. | |||||||||||||||
| |||||||||||||||
|
The impairment of GH release after clonidine in obese subjects might be in a reduced serotonin release or in a failure of the hypothalamic-pituitary system to stimulate plasma GH caused by a diminished GH releasing factor stimulatory effect or by an excessive endorphin or somatostatin secretion in obesity. | |||||||||||||||
| |||||||||||||||
|
There is evidence that dopamine and norepinephrine modulate the secretion of GH. | |||||||||||||||
| |||||||||||||||
|
Many years before native GHRH had been isolated and sequenced, the synthesis of an enkephalin analog, devoid of any opioid activity but capable of specifically releasing GH from in vitro pituitaries, prompted the design of a number of structurally interrelated GHRPs with improved GH-releasing activity. | |||||||||||||||
| |||||||||||||||
|
Nowadays, GHRPs are the most effective GH-secretagogues known and could be used profitably in humans with GH hyposecretory disturbances to promote a pattern of GH secretion that mimics physiology in a better way than the exogenously administered GH. | |||||||||||||||
| |||||||||||||||
|
After pre-treatment with cyproheptadine, an anti-serotoninergic drug known to inhibit GH secretion, the mean integrated sumatriptan-induced GH response decreased from 14.8 +/- 3.9 muI/l*hr to 3.7 +/- 1.7 mIU/l*hr. | |||||||||||||||
| |||||||||||||||
|
It is concluded that sumatriptan selectively increases GH secretion in man, but the exact nature of the receptors involved is not yet known. | |||||||||||||||
| |||||||||||||||
|
These tests both produced a wide variation in GH response in normal volunteers, considerable GH release following hp GRF 1-44 amide but little after clonidine in idiopathic GH deficiency, and indistinguishable, negligible responses in patients with craniopharyngiomas and pituitary tumours associated with GH deficiency. | |||||||||||||||
| |||||||||||||||
|
After placebo pretreatment, clonidine (0.15 mg iv infused over 20 min) significantly stimulated GH secretion: the mean serum GH level rose from a basal level of 4.7 +/- 1.1 (+/- SEM) ng/ml to a maximum of 10.8 +/- 1.6 ng/ml (P less than 0.025). | |||||||||||||||
| |||||||||||||||
|
It is concluded that the inhibitory effect of diazepam on human GH secretion is mediated via inhibition of dopaminergic transmission, whereas the alpha-adrenergic control of GH release is not affected. | |||||||||||||||
| |||||||||||||||
|
To establish whether diazepam affects the alpha-adrenergic regulation of GH secretion, the GH response to clonidine (an alpha-agonist) was investigated in seven volunteers after placebo and diazepam premedications. | |||||||||||||||
| |||||||||||||||
|
In addition, growth hormone (GH) secretion and serum insulin-like growth factor (IGF)-I levels fall. | |||||||||||||||
| |||||||||||||||
|
Pretreatment with clonidine clearly changed the pattern of GH release during GRF infusion: the amount of GH secreted was significantly higher, the number of GH peaks significantly increased, and almost all the GH was secreted within them. | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.